4/A: Pasithea Therapeutics Executive Corrects Stock Option Exercise Price in Amended SEC Filing

Graeme Currie, Chief Development Officer of Pasithea Therapeutics, files an amended Form 4 to correct the exercise price of a stock option granted on March 1, 2024.

Summary

• Graeme Currie, Chief Development Officer of Pasithea Therapeutics Corp., filed an amended Form 4 with the SEC.
• The amendment corrects the exercise price of a stock option granted on March 1, 2024.
• The original filing incorrectly stated the exercise price as $8.34 per share.
• The corrected exercise price is $8.13 per share, based on the closing price of Pasithea Therapeutics' common stock on March 1, 2024.
• The stock option, representing the right to buy 5,938 shares, was granted under the company's 2023 Stock Incentive Plan and fully vested upon issuance.
• A reverse stock split of 1-for-20 was effected on January 2, 2024, which adjusted the share amounts and exercise prices of outstanding equity awards.

Sentiment

Score: 6

Explanation: The document is a routine correction of a previously filed form, with no significant positive or negative implications for the company's financial health or future prospects. The sentiment is neutral.

Positives

• The stock option was granted under the 2023 Stock Incentive Plan, suggesting a commitment to incentivizing key personnel.
• The option fully vested upon issuance, indicating immediate value for the recipient.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in the biotechnology industry, used to align management's interests with those of shareholders.
• The vesting schedule and exercise price of stock options are typically benchmarked against industry peers to ensure competitiveness.
• Reverse stock splits are often undertaken by companies to increase their stock price and maintain listing requirements, a strategy employed by other companies in similar situations.

Stakeholder Impact

• Shareholders benefit from the increased transparency provided by the corrected SEC filing.
• The correction ensures accurate information regarding executive compensation and potential dilution.

Key Dates

Keywords

Form 4, Pasithea Therapeutics, Stock Option, Exercise Price, Amendment, Graeme Currie, Chief Development Officer, KTTA, Reverse Stock Split, SEC Filing